Compare Stocks: FTH, ENTX, ADCT, and IFRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.09 +7.9%	$1.15	$0.78 ▼ $4.98	$128.46M	1.89	875,833 shs	3.73 million shs
ENTX Entera Bio	$2.90 +0.3%	$2.05	$0.91 ▼ $4.20	$500.38M	1.38	4.94 million shs	304,792 shs
FTH Sensei Biotherapeutics	$32.77 +1.3%	$26.79	$7.21 ▼ $37.90	$835.68M	-0.25	289,796 shs	416,841 shs
IFRX InflaRx	$2.07 +1.5%	$1.90	$0.80 ▼ $2.95	$300.48M	2.48	956,630 shs	564,289 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	-10.59%	-25.83%	-68.15%	-67.99%
ENTX Entera Bio	0.00%	+0.70%	+45.96%	+134.96%	+44.50%
FTH Sensei Biotherapeutics	0.00%	+32.60%	+25.01%	+3,233,999,900.00%	+3,233,999,900.00%
IFRX InflaRx	0.00%	+10.87%	+9.97%	-18.40%	+136.41%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.09 +7.9%	$1.15	$0.78 ▼ $4.98	$128.46M	1.89	875,833 shs	3.73 million shs
ENTX Entera Bio	$2.90 +0.3%	$2.05	$0.91 ▼ $4.20	$500.38M	1.38	4.94 million shs	304,792 shs
FTH Sensei Biotherapeutics	$32.77 +1.3%	$26.79	$7.21 ▼ $37.90	$835.68M	-0.25	289,796 shs	416,841 shs
IFRX InflaRx	$2.07 +1.5%	$1.90	$0.80 ▼ $2.95	$300.48M	2.48	956,630 shs	564,289 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	-10.59%	-25.83%	-68.15%	-67.99%
ENTX Entera Bio	0.00%	+0.70%	+45.96%	+134.96%	+44.50%
FTH Sensei Biotherapeutics	0.00%	+32.60%	+25.01%	+3,233,999,900.00%	+3,233,999,900.00%
IFRX InflaRx	0.00%	+10.87%	+9.97%	-18.40%	+136.41%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	2.33	Hold	$5.00	358.72% Upside
ENTX Entera Bio	2.00	Hold	$9.00	210.34% Upside
FTH Sensei Biotherapeutics	2.83	Moderate Buy	$54.90	67.53% Upside
IFRX InflaRx	2.88	Moderate Buy	$7.33	254.27% Upside

Current Analyst Ratings Breakdown

Latest FTH, ENTX, ADCT, and IFRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
8/11/2026	FTH Sensei Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$60.00
8/7/2026	IFRX InflaRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
8/4/2026	FTH Sensei Biotherapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$55.00
7/31/2026	FTH Sensei Biotherapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$56.00
7/28/2026	FTH Sensei Biotherapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$60.00
7/27/2026	IFRX InflaRx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/20/2026	FTH Sensei Biotherapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$51.00
7/17/2026	ADCT ADC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ENTX Entera Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	FTH Sensei Biotherapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$81.36M	1.70	N/A	N/A	($1.50) per share	-0.73
ENTX Entera Bio	N/A	N/A	N/A	N/A	$0.29 per share	N/A
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$14.74 per share	N/A
IFRX InflaRx	$30K	10,163.01	N/A	N/A	$0.65 per share	3.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$142.62M	-$0.66	N/A	N/A	N/A	-121.77%	N/A	-32.74%	N/A
ENTX Entera Bio	-$11.44M	-$0.35	N/A	N/A	N/A	N/A	-147.19%	-103.22%	N/A
FTH Sensei Biotherapeutics	-$21.08M	-$141.65	N/A	N/A	N/A	N/A	-1,012.17%	-175.69%	N/A
IFRX InflaRx	-$51.63M	-$0.58	N/A	N/A	N/A	N/A	-53.56%	-43.02%	N/A

Latest FTH, ENTX, ADCT, and IFRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ADCT ADC Therapeutics	-$0.2160	-$0.11	+$0.1060	-$0.11	$18.89 million	$19.25 million
8/7/2026	Q2 2026	ENTX Entera Bio	-$0.08	-$0.14	-$0.06	-$0.14	N/A	N/A
8/6/2026	Q2 2026	IFRX InflaRx	-$0.0666	-$0.11	-$0.0434	-$0.10	$0.01 million	N/A
8/4/2026	Q2 2026	FTH Sensei Biotherapeutics	-$5.0450	-$2.84	+$2.2050	-$0.62	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	3.03	2.97
ENTX Entera Bio	N/A	8.98	8.98
FTH Sensei Biotherapeutics	N/A	19.69	19.69
IFRX InflaRx	N/A	8.22	8.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
ENTX Entera Bio	14.11%
FTH Sensei Biotherapeutics	10.50%
IFRX InflaRx	42.39%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.10%
ENTX Entera Bio	10.57%
FTH Sensei Biotherapeutics	7.00%
IFRX InflaRx	16.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	127.19 million	120.70 million	Optionable
ENTX Entera Bio	20	173.14 million	154.84 million	Optionable
FTH Sensei Biotherapeutics	40	25.84 million	24.03 million	Not Optionable
IFRX InflaRx	60	147.29 million	123.28 million	Optionable

FTH, ENTX, ADCT, and IFRX Headlines

Recent News About These Companies

InflaRx N.V.

August 11, 2026 | marketwatch.com

InflaRx (NASDAQ:IFRX) Price Target Raised to $6.00

August 10, 2026 | americanbankingnews.com

What is HC Wainwright's Estimate for InflaRx Q3 Earnings?

August 10, 2026 | americanbankingnews.com

HC Wainwright Estimates InflaRx's Q3 Earnings (NASDAQ:IFRX)

August 10, 2026 | marketbeat.com

InflaRx (NASDAQ:IFRX) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS

August 7, 2026 | marketbeat.com

Cantor Fitzgerald Increases InflaRx (NASDAQ:IFRX) Price Target to $6.00

August 7, 2026 | marketbeat.com

InflaRx Files Mid‑Year 2026 Unaudited Results in SEC Form 6‑K

August 6, 2026 | tipranks.com

InflaRx Reports Q2 2026 Results and Business Update, Advances Izicopan in AAV and Renal Diseases

August 6, 2026 | quiverquant.comQ

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

August 6, 2026 | globenewswire.com

InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of "Moderate Buy" from Analysts

July 30, 2026 | marketbeat.com

InflaRx to Report Second Quarter 2026 Results on August 6, 2026

July 30, 2026 | globenewswire.com

InflaRx (IFRX) to Announce Earnings on Thursday

July 30, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: InflaRx (IFRX) and Baxter International (BAX)

July 29, 2026 | theglobeandmail.com

InflaRx (NASDAQ:IFRX) Upgraded by Zacks Research to "Strong-Buy" Rating

July 29, 2026 | marketbeat.com

InflaRx (NASDAQ:IFRX) Trading Down 2.3% - Time to Sell?

July 27, 2026 | marketbeat.com

InflaRx (IFRX) Gets a Buy from Oppenheimer

July 18, 2026 | theglobeandmail.com

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe ...

June 30, 2026 | caledonianrecord.comC

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

June 30, 2026 | globenewswire.com

What Do Analysts Say About InflaRx N.V. (IFRX)?

June 10, 2026 | insidermonkey.com

Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now

May 31, 2026 | insidermonkey.com

Raymond James upgrades InflaRx NV (IFRX)

May 14, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH, ENTX, ADCT, and IFRX Company Descriptions

ADC Therapeutics NYSE:ADCT

$1.09 +0.08 (+7.92%)

As of 03:58 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Entera Bio NASDAQ:ENTX

$2.90 +0.01 (+0.35%)

As of 04:00 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Sensei Biotherapeutics NASDAQ:FTH

$32.77 +0.43 (+1.33%)

As of 04:00 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

InflaRx NASDAQ:IFRX

$2.07 +0.03 (+1.47%)

As of 04:00 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FTH, ENTX, ADCT, and IFRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FTH, ENTX, ADCT, and IFRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FTH, ENTX, ADCT, and IFRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH, ENTX, ADCT, and IFRX Company Descriptions

ADC Therapeutics NYSE:ADCT

Entera Bio NASDAQ:ENTX

Sensei Biotherapeutics NASDAQ:FTH

InflaRx NASDAQ:IFRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FTH, ENTX, ADCT, and IFRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FTH, ENTX, ADCT, and IFRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FTH, ENTX, ADCT, and IFRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH, ENTX, ADCT, and IFRX Company Descriptions

ADC Therapeutics NYSE:ADCT

Entera Bio NASDAQ:ENTX

Sensei Biotherapeutics NASDAQ:FTH

InflaRx NASDAQ:IFRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools